A class action lawsuit has been initiated against Ultragenyx Pharmaceutical Inc., with allegations that the company made materially false and misleading statements regarding the efficacy profile of setrusumab, its investigational treatment for Osteogenesis Imperfecta. According to the complaint, Ultragenyx allegedly failed to adequately disclose significant risks that emerged from Phase III clinical trial results and made representations of confidence in interim analysis that were primarily grounded in uncontrolled Phase II data.
The litigation targets investors who purchased Ultragenyx securities during a window spanning from August 3, 2023, through December 26, 2025. The complaint asserts that the company's statements regarding the drug candidate's potential therapeutic benefits did not appropriately reflect the limitations and uncertainties associated with the clinical development program, potentially resulting in investor losses when the company's disclosures were corrected.
Investors who acquired company securities during the specified period and believe they suffered financial harm as a result of the alleged misstatements are being advised to evaluate their eligibility to participate in the class action proceeding. The case represents one of several recent securities litigation matters involving pharmaceutical companies and allegations of inadequate clinical trial risk disclosure.